Myriad Jun 24, 2022 Myriad Genetics Partners with Epic Systems to Make Test Results Available in EMR May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium Mar 17, 2022 Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing Premium Mar 14, 2022 Myriad Genetics Launches New Comprehensive Suite of Cancer Tests With Research Registry Premium Sep 7, 2021 Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Jun 5, 2021 Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch Premium Jun 4, 2021 In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics Apr 27, 2021 Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M Mar 26, 2021 In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics Mar 24, 2021 Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering Premium Mar 2, 2021 Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service Jan 22, 2021 In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health Jan 12, 2021 JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More Jan 11, 2021 Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan Jan 8, 2021 In Brief This Week: Genentech, Myriad Genetics, Merus, Ambrx, and More Dec 9, 2020 Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project Nov 16, 2020 Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China Oct 15, 2020 Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests Jul 31, 2020 Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications Jul 1, 2020 Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers Load More Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
